All In Biotech

Drug Trial Radar · NCT00997997

Avelox in Complicated Skin and Skin Structure Infections

ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Nov 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6,127

Actual

Start

Oct 2005

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 20, 2009

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Conditions

  • Skin Diseases, Bacterial

Interventions

  • Moxifloxacin (Avelox, BAY12-8039)Drug

    400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of AveloxTime frame: last documented follow-up visit, according to the respective praxis routine

Locations

12 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Many Locations, Austria

  • Site not named

    Many Locations, Bulgaria

  • Site not named

    Many Locations, Egypt

  • Site not named

    Many Locations, Germany

  • Site not named

    Many Locations, Greece

  • Site not named

    Many Locations, Indonesia

  • Site not named

    Many Locations, Pakistan

  • Site not named

    Many Locations, Philippines

  • Site not named

    Many Locations, Saudi Arabia

  • Site not named

    Many Locations, Slovenia

  • Site not named

    Many Locations, South Korea

  • Site not named

    Many Locations, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.